These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 28229376

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.
    Lunde I, Bremer S, Midtvedt K, Mohebi B, Dahl M, Bergan S, Åsberg A, Christensen H.
    Eur J Clin Pharmacol; 2014 Jun; 70(6):685-93. PubMed ID: 24658827
    [Abstract] [Full Text] [Related]

  • 3. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
    Hu R, Barratt DT, Coller JK, Sallustio BC, Somogyi AA.
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):320-326. PubMed ID: 29603629
    [Abstract] [Full Text] [Related]

  • 4. Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus.
    Bruckmueller H, Werk AN, Renders L, Feldkamp T, Tepel M, Borst C, Caliebe A, Kunzendorf U, Cascorbi I.
    Ther Drug Monit; 2015 Jun; 37(3):288-95. PubMed ID: 25271728
    [Abstract] [Full Text] [Related]

  • 5. The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients.
    Zhang JJ, Liu SB, Xue L, Ding XL, Zhang H, Miao LY.
    Int J Clin Pharmacol Ther; 2015 Sep; 53(9):728-36. PubMed ID: 26227094
    [Abstract] [Full Text] [Related]

  • 6. Multigene predictors of tacrolimus exposure in kidney transplant recipients.
    Pulk RA, Schladt DS, Oetting WS, Guan W, Israni AK, Matas AJ, Remmel RP, Jacobson PA, DeKAF Investigators.
    Pharmacogenomics; 2015 Jul; 16(8):841-54. PubMed ID: 26067485
    [Abstract] [Full Text] [Related]

  • 7. Identification of factors affecting tacrolimus level and 5-year clinical outcome in kidney transplant patients.
    Kim IW, Noh H, Ji E, Han N, Hong SH, Ha J, Burckart GJ, Oh JM.
    Basic Clin Pharmacol Toxicol; 2012 Oct; 111(4):217-23. PubMed ID: 22469198
    [Abstract] [Full Text] [Related]

  • 8. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
    Deininger KM, Vu A, Page RL, Ambardekar AV, Lindenfeld J, Aquilante CL.
    Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
    [Abstract] [Full Text] [Related]

  • 9. The POR rs1057868-rs2868177 GC-GT diplotype is associated with high tacrolimus concentrations in early post-renal transplant recipients.
    Liu S, Chen RX, Li J, Zhang Y, Wang XD, Fu Q, Chen LY, Liu XM, Huang HB, Huang M, Wang CX, Li JL.
    Acta Pharmacol Sin; 2016 Sep; 37(9):1251-8. PubMed ID: 27498776
    [Abstract] [Full Text] [Related]

  • 10. Interactive effects of CYP3A4, CYP3A5, MDR1 and NR1I2 polymorphisms on tracrolimus trough concentrations in early postrenal transplant recipients.
    Li JL, Liu S, Fu Q, Zhang Y, Wang XD, Liu XM, Liu LS, Wang CX, Huang M.
    Pharmacogenomics; 2015 Sep; 16(12):1355-65. PubMed ID: 26228923
    [Abstract] [Full Text] [Related]

  • 11. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus.
    Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, Weimar W, van Gelder T.
    Clin Pharmacol Ther; 2003 Sep; 74(3):245-54. PubMed ID: 12966368
    [Abstract] [Full Text] [Related]

  • 12. Influence of cytochrome P450 3A5 polymorphisms on viral infection incidence in kidney transplant patients treated with tacrolimus.
    Hattori Y, Tanaka H, Teranishi J, Ishida H, Makiyama K, Miyajima E, Noguchi K, Kubota Y.
    Transplant Proc; 2014 Sep; 46(2):570-3. PubMed ID: 24656015
    [Abstract] [Full Text] [Related]

  • 13. Switching Immunosuppression From Cyclosporine to Tacrolimus in Kidney Transplant Recipients Based on CYP3A5 Genotyping.
    Wang X, Yang Y, Liu Z, Xiao C, Gao L, Zhang W, Zhang W, Wang Z.
    Ther Drug Monit; 2019 Feb; 41(1):97-101. PubMed ID: 30520827
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. P450 oxidoreductase *28 (POR*28) and tacrolimus disposition in pediatric kidney transplant recipients--a pilot study.
    Gijsen VM, van Schaik RH, Soldin OP, Soldin SJ, Nulman I, Koren G, de Wildt SN.
    Ther Drug Monit; 2014 Apr; 36(2):152-8. PubMed ID: 24089076
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
    Nair SS, Sarasamma S, Gracious N, George J, Anish TS, Radhakrishnan R.
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.